Levodopa formulations
Standard and extended-release levodopa-carbidopa, intestinal gel, inhaled and sublingual formulations — dosing strategies and off-time control.
State of the art
No update yet for Levodopa formulations. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
-
Levodopa increases substantia nigra iron: implications for Parkinson's disease
The study raises a mechanistic concern applicable to all levodopa formulations: that the drug may raise nigral iron as a side-effect of its metabolism, a finding relevant to discussions about when to start levodopa and at what dose. -
Phase 3 trial of solengepras for Parkinson’s disease now fully enrolled
The ARISE trial tests solengepras specifically as an add-on to existing levodopa therapy, addressing the gap of patients whose off time is not adequately controlled by levodopa alone — a common and persistent problem in long-term disease management. -
Vyalev eases motor, nonmotor symptoms in advanced Parkinson’s
ROSSINI provides the first prospective real-world effectiveness data for foslevodopa/foscarbidopa (Vyalev) — a subcutaneous prodrug formulation — showing comparable efficacy to its Phase 3 trial results and a safety profile consistent with prior controlled studies, including ~6% rates of hallucinations and infusion-site infections.